A Phase 2 interventional study of Xalatan in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 2, Interventional, and Treatment
Compare the antihypertensive efficacy of three methods for installing Xalatan
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
Browse Glaucoma studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 431 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
IOP level in the study eye
Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period
No study locations are listed for this record.
This study is withdrawn, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.